迪巧品牌怎么样 申请店铺

我要投票 迪巧在钙片行业中的票数:88 更新时间:2024-12-22
迪巧是哪个国家的品牌?「迪巧」是安士制药(中山)有限公司旗下著名品牌。该品牌发源于广东,由创始人徐清波在2003-09-19期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
迪巧怎么样

迪巧是由美国安士制药有限公司按F.LA标准在美国生产的品牌产品。精选全球50多个优质钙源,是经过国际先进工艺提纯的精制碳酸钙,安全性极高。迪巧科学添加了维生素D3,具有安全、足量、好吸收的三大优点。同时,迪巧针对中国不同年龄段人群对钙制剂需求的特点,特别设计了个性配方和口味。有专为0-3岁宝宝设计的迪巧小儿碳酸钙D3颗粒,专为3岁以上儿童设计的迪巧儿童维D钙咀嚼片,专为成人计的迪巧维D钙咀嚼片以及专为更年期女性设计的迪巧秀源女性片。

迪巧是中国优生科学协会唯一推荐钙补充剂,经中国优生科学协会审核论证,连续10年被作为唯一推荐补钙制剂。2010年中国家庭药箱调查显示,迪巧名列中国居民信赖的家庭常备药排名前三。该调查由中国非处方药物协会、中国医药质量管理协会、中国药学会发布。迪巧荣获中国健康年度总评榜“最受欢迎补钙用药”。2010年39健康网开展了健康年度总评榜,由网民自行投票选出最欢迎的药品品牌,迪巧荣获最受欢迎补钙用药之一。迪巧连续3年荣获“健康中国2010中国药品品牌榜”上榜品牌称号。迪巧连续3年荣获“2008-2009年度店员推荐率最高品牌”。2009年10月29日至31日,《中国药店》杂志社举办了第九届中国药店高峰论坛暨"2008-2009年度店员推荐率最高品牌"揭晓会议,来自全国连锁店、及卫生部、国家药监局的百余人到场。迪巧深受药店专业人员信赖,被大会评为“2008-2009年度店员推荐率最高品牌”。这已经是迪巧连续三年荣获此奖项。

安士制药(中山)有限公司位于广东省中山市火炬开发区国家健康基地,是由以美国安士集团有限公司,中山市健康科技产业基地发展有限公司和百洋集团有限公司为主的几家公司共同投资的一家集科研开发、生产和市场建设于一体的新型医药生产企业。

公司首期占地面积二万多平方米,拥有近一万四千平方米的现代化厂房,已建成两个固体制剂车间、冻干粉针车间、软胶囊车间和质检中心。全部生产车间都通过了国家和省食品药品监督管理局认证中心的GMP认证。固体制剂车间于2010年5月通过美国FDA现场验证。

安士以科研开发为先导,研究开发自产产品。同时引进国外先进生产技术及产品信息,已形成的迪巧系列补钙制剂为国内名列前茅的大品种。此外,安士一直致力于处方药出口美国为主攻目标,培育一支适应国际化生产要求的管理团队和员工队伍。

2007年3月,安士生物科技(中山)有限公司成立,专门从事保健品的软胶囊研发和生产,从而满足软胶囊制剂在国内外市场销售快速发展的需要。

安士制药(中山)有限公司的宗旨是进一步提高安士品牌的美誉度和信任度,极大地丰富安士与人类健康息息相关的品牌内涵。公司的目标是建立一个适应新剂型、新品种发展的药品生产基地,努力在制药市场上形成一个重要的、诚信可靠的企业,为人类的健康事业做出贡献。

Diqiao is a brand product manufactured in the United States by axis Pharmaceutical Co., Ltd. according to f.la standard. More than 50 high-quality calcium sources in the world are selected. They are refined calcium carbonate purified by international advanced technology, with high safety. Diqiao added vitamin D3 scientifically, which has three advantages of safety, sufficient quantity and good absorption. At the same time, Diqiao specially designed the individual formula and taste according to the characteristics of different age groups in China. There are Diqiao children's calcium carbonate D3 granules specially designed for 0-3 years old children, Diqiao children's vitamin D calcium chewable tablets specially designed for children over 3 years old, Diqiao vitamin D calcium chewable tablets specially designed for adults and Diqiao Xiuyuan women's tablets specially designed for menopausal women. Diqiao is the only calcium supplement recommended by China eugenics Association. It has been the only calcium supplement recommended by China eugenics Association for 10 consecutive years. According to the 2010 survey of family medicine kits in China, Diqiao ranked in the top three list of household medicines trusted by Chinese residents. The survey was released by China over the counter drug association, China Pharmaceutical Quality Management Association and China Pharmaceutical Association. Diqiao won the "most popular calcium supplement" in China's annual health review. In 2010, 39 health.com launched the annual health evaluation list, and the Internet users voted to select the most popular drug brand. Diqiao won one of the most popular calcium supplements. Diqiao has won the title of "healthy China 2010 Chinese drug brand list" for three consecutive years. Diqiao has been awarded "the highest brand recommended by shop assistants in 2008-2009" for three consecutive years. From October 29 to 31, 2009, China drugstore magazine Co., Ltd. held the 9th China drugstore Summit Forum and the unveiling meeting of "the highest recommended brand of staff in 2008-2009". More than 100 people from the national chain stores, the Ministry of health and the State Food and Drug Administration attended. Diqiao is deeply trusted by drugstore professionals and was rated as the "top brand with the highest recommended rate of salesmen in 2008-2009" by the conference. This is the third consecutive year that Diqiao has won this award. Anshi Pharmaceutical (Zhongshan) Co., Ltd. is located in the national health base of Torch Development Zone, Zhongshan City, Guangdong Province. It is a new pharmaceutical production enterprise, which is jointly invested by several companies mainly including Anshi Group Co., Ltd., Zhongshan Health Science and Technology Industrial Base Development Co., Ltd. and Baiyang Group Co., Ltd. The first phase of the company covers an area of more than 20000 square meters, with a modern plant of nearly 14000 square meters. Two solid preparation workshops, freeze-dried powder injection workshops, soft capsule workshops and quality inspection centers have been built. All production workshops have passed the GMP certification of national and provincial food and Drug Administration certification center. The solid preparation workshop passed the FDA field verification in May 2010. With scientific research and development as the guide, axis researches and develops its own products. At the same time, the introduction of foreign advanced production technology and product information, has formed Diqiao series of calcium supplements for the domestic top big varieties. In addition, axis has been committed to the export of prescription drugs to the United States as the main goal, and cultivate a management team and staff team to meet the requirements of international production. In March 2007, axis Biotechnology (Zhongshan) Co., Ltd. was established, specializing in the research, development and production of soft capsules for health products, so as to meet the needs of rapid development of soft capsule sales in domestic and foreign markets. The aim of axis Pharmaceutical (Zhongshan) Co., Ltd. is to further improve the reputation and trust of axis brand and greatly enrich the brand connotation of axis closely related to human health. The company's goal is to establish a pharmaceutical production base to adapt to the development of new dosage forms and new varieties, strive to form an important, honest and reliable enterprise in the pharmaceutical market, and make contributions to human health.

本文链接: https://brand.waitui.com/7cdc17c05.html 联系电话:076023898866

千城特选小程序码

7×24h 快讯

突破80万吨 郑州机场年货邮吞吐量刷新通航以来最高纪录

12月22日,中原龙浩航空B747全货机从金奈飞抵郑州,标志着郑州机场今年货邮吞吐量已突破80万吨,创下1997年通航以来年货邮吞吐量历史新高。今年以来,郑州机场新开货运航线19条,单日货运航班量最多90架次,单月货运量在9月、10月、11月分别突破7.6万吨、8万吨和8.6万吨,持续刷新纪录。在全国50万吨以上机场中,郑州机场货邮吞吐量增速位列第2。

27分钟前

GGII:预计2024年中国工业机器人全年销量约30万台,同比下滑5%左右

高工机器人产业研究所(GGII)预计2024年中国工业机器人全年销量约30万台,同比下滑5%左右。从需求端角度看,工业机器人下游应用领域延续分化态势,三大基本盘(汽车及零部件、3C、新能源)中仅3C电子与汽车零部件行业增长相对亮眼,汽车整车与新能源行业承压明显,尤其是新能源行业,需求呈现大幅下滑态势;食品、金属制品等行业呈现稳健增长态势;半导体行业受益于行业需求的释放,需求增长亮眼,不少晶圆搬运机器人厂商受益其中;物流仓储行业延续承压态势,需求呈下滑趋势。其它一般工业鲜有明显复苏迹象,GGII判断,需求问题已成为当前产业链核心矛盾点。从企业层面来看,内外资企业分化加剧,从前三季度业绩增长情况来看,国产头部企业业绩增长均高于外资厂商。(界面)

27分钟前

上海航交所:本周商品市场博弈加剧,沿海综合运价指数大幅下跌

据上海航交所,本周,2025年度煤电长协谈判博弈加剧,终端电厂以消化现有库存为主,运输市场货盘稀少,综合指数持续下行。12月20日,上海航运交易所发布的中国沿海(散货)综合运价指数报收1061.31点,较上期下跌5.5%。(界面新闻)

27分钟前

李斌:蔚来ET9订单超预期,首发999辆全卖完

12月22日,蔚来创始人、董事长李斌对外表示,蔚来ET9首发限量版已卖完,订单量超预期。在12月21日举行的NIO Day2024上,蔚来旗下智能电动行政旗舰车型——ET9正式上市,整车购买方案起售价为78.8万元,电池租用方案起售价为66万元。蔚来推出了999辆ET9首发限量版车型,售价为81.8万元。据李斌透露,蔚来ET9将于明年3月正式开启交付,优先交付首发限量版。(证券时报)

27分钟前

本田与日产将率先磋商合并,三菱汽车或明年年初再做决定

12月21日消息,据悉,本田和日产汽车23日起将正式启动经营合并磋商,三菱汽车则在协调于明年年初决定是否参与合并,弄清以何种方式进入持股公司等条件。 三家公司社长23日将向日本经济产业省和国土交通省汇报,然后召开记者会正式发布消息。 据悉,在本田和日产的经营合并磋商中,双方将探讨在彼此工厂相互生产汽车的方式,探讨由本田向在美国缺乏畅销车型的日产供应混动车的方案。两家公司计划在广泛领域展开合作,但本田提出把日产业绩“V型复苏”作为合并的条件。(共同社)

27分钟前

本页详细列出关于龙牡的品牌信息,含品牌所属公司介绍,龙牡所处行业的品牌地位及优势。
咨询